Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial

Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion: A Pooled Analysis of the EXTEND-IA TNK Trials

(2022) Vignan Yogendrakumar et al.   NEUROLOGY

Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke

(2020) Bruce C. V. Campbell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Do Clinicians Overestimate the Severity of Intracerebral Hemorrhage?

(2019) Elliot J. Tilling et al.   STROKE

Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke

(2019) Christopher Elnan Kvistad et al.   STROKE

Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke

(2019) Adrian M. Burgos et al.   STROKE

Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST)

(2018) Christopher Elnan Kvistad et al.   International Journal of Stroke

Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke

(2018) Bruce C.V. Campbell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

(2017) Nicola Logallo et al.   LANCET NEUROLOGY

Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis

(2016) William N Whiteley et al.   LANCET NEUROLOGY

Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke

(2015) Nicola Logallo et al.   CNS DRUGS

Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study

(2015) Xuya Huang et al.   LANCET NEUROLOGY

Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion

(2015) Shelagh B. Coutts et al.   STROKE

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

(2014) Jonathan Emberson et al.   LANCET

A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke

(2012) Mark Parsons et al.   NEW ENGLAND JOURNAL OF MEDICINE

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

(2010) Kennedy R Lees et al.   LANCET

Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke

(2010) E. Clarke Haley et al.   STROKE

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

(2008) Werner Hacke et al.   NEW ENGLAND JOURNAL OF MEDICINE